discontinuing glp-1 ISPOR 2025: Exploring reasons for discontinuation Examining the consequences of discontinuing

If disease activity remains inadequately controlled, treatment should escalate to combination conventional synthetic DMARDs or biological agents following a treat-to-target approach

Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus

The gut barrier is supposed to keep potentially inflammatory proteins from entering our bloodstream, where they can trigger an immune response, even contributing to autoimmunity

Many people regain weight when they stop taking them, which is why patients should think carefully about whether they are ready for long-term treatment, at least until we have better evidence on how to maintain weight loss after stopping medication or treatments that more durably change the course of obesity

According to current guidelines, asymptomatic gallstones generally do not require intervention, and decisions should be individualized based on symptoms and overall clinical picture